Player FM - Internet Radio Done Right
Checked 2+ y ago
Lagt til eight år siden
Innhold levert av cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!
Gå frakoblet med Player FM -appen!
How is the Heng Criteria Applied to Kidney Cancer Patients?
Manage episode 153141026 series 1082357
Innhold levert av cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Dr. Daniel Heng is the namesake of the Heng Criteria, which evaluates various factors of kidney cancer patients to determine their prognoses.
307 episoder
Manage episode 153141026 series 1082357
Innhold levert av cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Dr. Daniel Heng is the namesake of the Heng Criteria, which evaluates various factors of kidney cancer patients to determine their prognoses.
307 episoder
Alle episoder
×1 Should Small Cell Lung Cancer Patients Who Respond to Chemo Receive Consolidation Radiotherapy? 4:36
4:36
Spill senere
Spill senere
Lister
Lik
Likt
4:36Dr. Nasser Hanna outlines the possible benefits of consolidation chest radiation for small cell lung cancer patients who respond well to chemotherapy.
What puts you at risk for inherited kidney cancer? Dr. Nizar Tannir discusses the signs doctors look for to determine if a kidney cancer patient should be screened for a familial syndrome.
1 Should All Small Cell Lung Cancer Patients Receive Prophylactic Cranial Irradiation? 5:28
5:28
Spill senere
Spill senere
Lister
Lik
Likt
5:28The doctors discuss the circumstances under which small cell lung cancer patients should receive prophylactic cranial irradiation.
NanoString Technology may help doctors learn what is driving tumor growth in kidney cancer patients and, therefore, determine what treatments may be most effective for them.
1 Is Necitumumab An Effective Antibody Against EGFR for Patients with Squamous Lung Cancer? 2:27
2:27
Spill senere
Spill senere
Lister
Lik
Likt
2:27Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.
1 How is the Heng Criteria Applied to Kidney Cancer Patients? 4:40
4:40
Spill senere
Spill senere
Lister
Lik
Likt
4:40Dr. Daniel Heng is the namesake of the Heng Criteria, which evaluates various factors of kidney cancer patients to determine their prognoses.
1 Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment? 7:28
7:28
Spill senere
Spill senere
Lister
Lik
Likt
7:28The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
Dr. Lauren Harshman explains what PD1 (an immune T-cell) and PDL1 (a protein on the PD1 T-cell) are and how new drugs impact them to fight kidney cancer.
1 Zykadia for ALK Positive Lung Cancer: New Drug, New Hope 7:22
7:22
Spill senere
Spill senere
Lister
Lik
Likt
7:22The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.
1 No Clear Answer for Non-Clear Cell Kidney Cancer 5:41
5:41
Spill senere
Spill senere
Lister
Lik
Likt
5:41Drugs in early stage clinical trials seem to show benefit for non-clear cell kidney cancer, but more trials must take place and patients are desperately needed to enroll in them.
1 What Went Wrong? The Failure of MetMab with Tarceva in Advanced Non-Small Cell Lung Cancer 3:52
3:52
Spill senere
Spill senere
Lister
Lik
Likt
3:52"Dead negative," is how Dr. Nasser Hanna describes results of a phase 3 study that examined how patients with high MET expression did on the drug MetMab (onartuzumab).
Dr. Guru Sonpavde discusses what he does when he first begins treating a patient recently diagnosed with late stage kidney cancer.
1 MET-Amplified Lung Cancer: A New Target for XALKORI? 7:18
7:18
Spill senere
Spill senere
Lister
Lik
Likt
7:18Lung cancer patients with high MET amplification appear to do well on Xalcori (crizotinib), a drug that is approved for ALK positive patients.
1 The Hottest Thing in Late Stage Kidney Cancer 2:35
2:35
Spill senere
Spill senere
Lister
Lik
Likt
2:35Patients are responding very well to the next generation of immunotherapy drugs currently in clinical trials to treat kidney cancer.
1 CO1686 - 3rd Generation Drug for Acquired Resistance in EGFR Lung Cancer 4:10
4:10
Spill senere
Spill senere
Lister
Lik
Likt
4:10Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.
Velkommen til Player FM!
Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.